Heplisav-B Market Report 2026

Heplisav-B Market Overview

• The Heplisav-B market growth in the historic period has been driven by low compliance with three dose vaccines, rising hepatitis b burden in adults • Market expansion is supported by expansion of adult vaccination mandates, increasing focus on diabetic and liver disease patients • Growth Driver: Rising Prevalence Of Hepatitis B Infections Driving Market Growth • Market Trend: Advancements In Hepatitis B Vaccination • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Heplisav-B Market?

Heplisav-B is a recombinant vaccine designed to protect adults aged 18 and older against hepatitis B. It contains hepatitis B surface antigen (HBsAg) and an advanced adjuvant (1018) to enhance immune response. Administered as a two-dose series over one month, Heplisav-B offers higher seroprotection rates and greater convenience compared to traditional three-dose vaccines, making it particularly effective for high-risk individuals such as healthcare workers, those with chronic liver disease, or people with diabetes. The main typs of heplisav-B products are vaccines and combination vaccines. Vaccines are biological preparations that provide immunity to a specific infectious disease by stimulating the body's immune system to recognize and fight pathogens. It is used for adult hepatitis b prevention and special populations and is distributed through integrated delivery networks (idns) and large clinics, retail pharmacies, and hospitals.

What Is The Heplisav-B Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of adult vaccination mandates, increasing focus on diabetic and liver disease patients, wider adoption by integrated delivery networks, growth in employer sponsored vaccination programs, continued emphasis on preventive healthcare. Major trends in the forecast period include two dose adult hepatitis b vaccination adoption, rising preference for high seroprotection vaccines, growth in vaccination among high risk adult populations, shift toward convenience driven immunization schedules, expansion of workplace and occupational vaccination programs.

Global Heplisav-B Market Segmentation

1) By Product Type: Vaccines, Combination Vaccines 2) By Indication: Adult Hepatitis B Prevention, Special Populations 3) By Distribution Channel: Integrated Delivery Networks (IDNs) And Large Clinics, Retail Pharmacies, Hospitals

What Are The Drivers Of The Heplisav-B Market?

The increasing prevalence of hepatitis B infections is expected to boost the growth of the heplisav-B market going forward. Hepatitis B infections are liver diseases caused by the hepatitis B virus (HBV), which can lead to acute or chronic conditions, including cirrhosis and liver cancer. The prevalence of hepatitis B infections is rising due to low vaccination rates, high-risk group transmission, limited awareness, and inadequate healthcare access. Heplisav-B is a vaccine used to prevent hepatitis B infection by stimulating the immune system to produce protective antibodies. For instance, April 2025, according to Centers for Disease Control and Prevention, U.S-based government agency reported that, in 2023, there were 2,214 new cases of acute hepatitis B reported. Further, there were 1,769 hepatitis B-related deaths reported during 2023. Therefore, the increasing prevalence of hepatitis B infections will drive the growth of the heplisav-B industry. The rising prevalence of chronic diseases is expected to drive the growth of the heplisav-B market going forward. Chronic disease is a long-term health condition that typically progresses slowly, persists for an extended period, and often requires ongoing medical care and lifestyle management. The rising prevalence of chronic diseases is driven by factors such as aging populations, lifestyle changes, inadequate healthcare access, and increased environmental exposures. Heplisav-b is required for the management of chronic diseases, particularly in individuals with weakened immune systems, as it provides a stronger and longer-lasting immune response to protect against hepatitis B infection. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases will drive the growth of the heplisav-B industry.

Key Players In The Global Heplisav-B Market

Major companies operating in the heplisav-b market are Dynavax Technologies Corporation

Global Heplisav-B Market Trends and Insights

The key trend in the heplisav-B market is focusing on developing innovative products, such as hepatitis b adjuvanted vaccines, to provide stronger and longer-lasting immune responses. A hepatitis B adjuvanted vaccine is an immunization that includes an adjuvant to enhance the body's immune response to the hepatitis B surface antigen, improving vaccine efficacy, especially in populations with weaker immune systems. For instance, in February 2023, Dynavax Technologies Corporation, a US-based biopharmaceutical company, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Heplisav-B for marketing in Great Britain. This vaccine is designed for adults and is approved for active immunization against all known subtypes of the hepatitis B virus (HBV) in individuals aged 18 years and older. The approval was based on favorable safety and immunogenicity outcomes demonstrated in three Phase 3 clinical trials. Heplisav-B combines the hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist adjuvant, CpG 1018, to enhance the immune response. Dynavax holds the global commercial rights to Heplisav-B.

Regional Insights

North America was the largest region in the heplisav-B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Heplisav-B Market?

The heplisav-B market consists of sales of adjuvants, immunology products, diagnostic kits, and therapeutic vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Heplisav-B Market Report 2026?

The heplisav-b market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the heplisav-b industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.